Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Articles

Watershed Moment for Cell Therapies and Complic...

In recent years, the development of cell and gene therapies has provided a new avenue for the treatment of rare disorders. This article will discuss the current and future scenarios of cell and gen...

May 08, 2023

gsk-respiratory-syncytial-virus-vaccine
GSK Is All Set To Launch Respiratory Syncytial Virus Vaccine… Now Who’s Next?

Infections due to respiratory syncytial virus (RSV) have seriously troubled drug makers for decades and the need for a vaccine was on since the 1960s. According to the assessment done by DelveInsight on the latest published “Respiratory Syncytial Virus Epidemiology Report,” it is estimated to affect approximately 5...

Find More
cancer-diagnostics-market-landscape
Cancer Diagnostic Market: Evaluating the Major Growth Factors and the Key Developments in the Domain

Cancer is a global burden, leading to a significant number of death and disabilities worldwide. In 2020, nearly one in six deaths were related to cancer. Breast cancer, lung cancer, colon and rectum cancer, and prostate cancer are some of the major cancer types, registering the highest number of cases globally. To ...

Find More
cell-and-gene-therapies-for-diabetes-treatment
Cell and Gene Therapies for Diabetes Treatment: A Permanent Cure for Patients?

Diabetes is the 8th largest cause of death in the United States (although its prevalence may be underreported). Diabetes affects more than 37 million people in the United States, and 1 in every 5 are unaware of their condition. Over 96 million US adults—more than one-third—have prediabetes, and more than 8 out of 1...

Find More

More Views & Analysis

roche-polivy-adc-for-dlbcl-treatment
Roche’s CD79b ADC POLIVY: Attempt to Change DLBCL Treatment Space

In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of antibody-drug conjugates (ADCs). These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them togethe...

Find More

emerging-therapies-for-non-cystic-fibrosis-bronchiectasis-treatment
Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment: The Quest for Effective Therapies

Bronchiectasis is a chronic respiratory condition where the bronchial tubes in the lungs become damaged, inflamed, and widened, leading to a buildup of mucus that makes breathing difficult. The condition can develop for various reasons, including infections, genetic disorders, autoimmune conditions, and other facto...

Find More

emerging-vaccines-for-respiratory-syncytial-virus-treatment
Respiratory Syncytial Virus Treatment Market: A Complex Space Worth Billions!

Respiratory syncytial virus is estimated to affect approximately 5 million cases this year in the United States and 2.5 million RSV cases in the EU4 countries and the United Kingdom. As per Delveinsight analysis on the latest published “Respiratory Syncytial Virus Epidemiology Report,” the US comprised ~70%, ~27%, ...

Find More

Body Contouring Devices Market Outlook
Body Contouring Devices: Understanding the Key Factors Determining the Market Growth and Evolving Trends

Body Contouring is a highly evolving concept in the field of cosmetic dermatology, and the demand for these devices to improve the body's appearance is growing at an immense rate. Some of the products have demonstrated excellent clinical efficacy and safety. With the rising awareness regarding noninvasive and minim...

Find More

roches-her2-positive-breast-cancer-therapies
Roche’s HER2-Positive Breast Cancer Treatment Franchise

For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...

Find More

vertex-crispr-gene-editing-therapy-exa-cel
Vertex/CRISPR’s Gene-editing Therapy exa-cel: Inch Ahead of Rival

Vertex Pharma and CRISPR Therapeutics are the first companies to seek FDA clearance for a gene-editing therapy. Vertex Pharmaceuticals and CRISPR Therapeutics have gotten closer to introducing exagamglogene autotemcel (exa-cel), a one-time treatment for sickle cell disease (SCD) and transfusion-dependent beta-...

Find More

Market intelligence (MI) is described as the information or the data derived by a company from the m.....

Find More

Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....

Find More

Celiac disease is an autoimmune disorder against the gluten consumed that creates toxins, thereby, d.....

Find More

Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are cha.....

Find More

An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....

Find More

Value-Based Healthcare is that healthcare model or a process where the providers, including hospital.....

Find More